Table 2.
Characteristics of patients in the G3S and IPC cohorts, proportion of eligible patients for TARGIT E and RIOP trials
| G3S (n = 1411) | IPC (n = 592) | p | ||
|---|---|---|---|---|
| Age | 70–79 | 1213 (86%) | 488 (82.4%) | <0.05 |
| ≥80 | 198 (14%) | 104 (17.6%) | ||
| pN | pN0 | 1113 (78.9%) | 407 (76%) | 0.05 |
| pN1 | 297 (21.1%) | 143 (24%) | ||
| Tumor type | Ductal | 1064 (75.4%) | 515 (87%) | <0.0001 |
| Lobular | 177 (12.5%) | 67 (11.3%) | ||
| Mixed | 28 (2%) | 9 (1.5%) | ||
| Other | 137 (9.7%) | 1 (0.2%) | ||
| Tumor size | ≤20 mm | 1186 (84.6%) | 402 (51.4%) | <0.0001 |
| >20 mm | 216 (15.4%) | 380 (48.6%) | ||
| Grade | 1 | 473 (33.9%) | 196 (67.9%) | <0.02 |
| 2 | 718 (51.5%) | 271 (47.3%) | ||
| 3 | 185 (13.3%) | 106 (18.5%) | ||
| unknown | 18 (1.3%) | 19 (3.3%) | ||
| Lymphovascular invasion | Yes | 150 (13%) | 154 (27.8%) | <0.0001 |
| No | 1004 (87%) | 399 (67.4%) | ||
| Hormonal receptor | positive | 1243 (90.5%) | 405 (69%) | <0.0001 |
| negative | 131 (9.5%) | 182 (31%) | ||
| Local recurrences | Yes | 17 (1.2%) | 18 (3%) | <0.01 |
| no | 1394 (98.8%) | 574 (97%) | ||
| Eligible patients RIOP (RE) | Yes | 499 (36.8%) | 114 (19.3%) | <0.0001 |
| no | 856 (63.2%) | 478 (80.7%) | ||
| Eligible patients TARGIT E (TE) | Yes | 859 (60.9%) | 268 (45.3%) | <0.0001 |
| no | 552 (39.1%) | 324 (54.7%) |